| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcus agalactiae | 44 | 2013 | 79 | 5.020 |
Why?
|
| Communicable Diseases, Emerging | 13 | 2019 | 21 | 3.490 |
Why?
|
| Disease Outbreaks | 28 | 2022 | 115 | 3.460 |
Why?
|
| Population Surveillance | 13 | 2024 | 206 | 2.750 |
Why?
|
| Streptococcal Infections | 29 | 2013 | 80 | 2.560 |
Why?
|
| Antigens, Surface | 20 | 2009 | 196 | 2.340 |
Why?
|
| Bacterial Proteins | 27 | 2013 | 769 | 2.050 |
Why?
|
| Internet | 10 | 2016 | 466 | 1.890 |
Why?
|
| Global Health | 13 | 2021 | 183 | 1.660 |
Why?
|
| Influenza, Human | 7 | 2024 | 207 | 1.360 |
Why?
|
| Epidemiological Monitoring | 8 | 2025 | 31 | 1.340 |
Why?
|
| Antigens, Bacterial | 13 | 2008 | 207 | 1.140 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2014 | 89 | 1.120 |
Why?
|
| Electronic Mail | 4 | 2017 | 45 | 1.050 |
Why?
|
| Pandemics | 7 | 2024 | 667 | 0.880 |
Why?
|
| Epidemics | 4 | 2019 | 24 | 0.880 |
Why?
|
| Communicable Disease Control | 3 | 2019 | 42 | 0.860 |
Why?
|
| Public Health | 9 | 2024 | 187 | 0.810 |
Why?
|
| Vaccines | 3 | 2016 | 96 | 0.800 |
Why?
|
| Glycosaminoglycans | 3 | 2008 | 19 | 0.790 |
Why?
|
| Foodborne Diseases | 2 | 2020 | 6 | 0.730 |
Why?
|
| Vaccination | 8 | 2025 | 358 | 0.720 |
Why?
|
| Humans | 100 | 2025 | 62933 | 0.700 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 7 | 2003 | 81 | 0.700 |
Why?
|
| Massachusetts | 17 | 2025 | 2061 | 0.670 |
Why?
|
| Streptococcal Vaccines | 5 | 2008 | 5 | 0.610 |
Why?
|
| Communicable Diseases | 6 | 2017 | 90 | 0.600 |
Why?
|
| Sentinel Surveillance | 4 | 2023 | 19 | 0.580 |
Why?
|
| Public Opinion | 3 | 2020 | 24 | 0.580 |
Why?
|
| Epithelial Cells | 7 | 2008 | 390 | 0.580 |
Why?
|
| Pneumococcal Infections | 4 | 2025 | 38 | 0.580 |
Why?
|
| Antibodies, Bacterial | 13 | 2008 | 194 | 0.570 |
Why?
|
| Information Services | 2 | 2006 | 35 | 0.500 |
Why?
|
| Streptococcus pneumoniae | 5 | 2025 | 66 | 0.500 |
Why?
|
| Plant Diseases | 2 | 2014 | 12 | 0.500 |
Why?
|
| Immunization | 6 | 2016 | 133 | 0.490 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 206 | 0.480 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2014 | 1 | 0.460 |
Why?
|
| Animals | 39 | 2025 | 20643 | 0.450 |
Why?
|
| Epidemiologic Methods | 1 | 2013 | 66 | 0.410 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 89 | 0.410 |
Why?
|
| Intensive Care Units | 2 | 2020 | 403 | 0.390 |
Why?
|
| Health Status Disparities | 1 | 2013 | 144 | 0.380 |
Why?
|
| Information Storage and Retrieval | 2 | 2009 | 60 | 0.380 |
Why?
|
| Polysaccharides, Bacterial | 6 | 2006 | 45 | 0.370 |
Why?
|
| Public Health Informatics | 1 | 2011 | 8 | 0.370 |
Why?
|
| Genome, Viral | 3 | 2021 | 136 | 0.360 |
Why?
|
| Electronic Health Records | 3 | 2024 | 355 | 0.350 |
Why?
|
| Pneumococcal Vaccines | 2 | 2025 | 20 | 0.350 |
Why?
|
| Female | 38 | 2025 | 32592 | 0.350 |
Why?
|
| Dengue | 1 | 2011 | 96 | 0.350 |
Why?
|
| Genes, Bacterial | 6 | 2006 | 121 | 0.340 |
Why?
|
| Bacterial Translocation | 2 | 2007 | 11 | 0.340 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2025 | 12 | 0.340 |
Why?
|
| Sequence Deletion | 3 | 2001 | 117 | 0.340 |
Why?
|
| Bacterial Vaccines | 6 | 1999 | 87 | 0.340 |
Why?
|
| Pregnancy | 13 | 2019 | 2325 | 0.330 |
Why?
|
| Vaccines, Conjugate | 7 | 2014 | 18 | 0.330 |
Why?
|
| Mass Media | 3 | 2020 | 31 | 0.330 |
Why?
|
| Molecular Sequence Data | 15 | 2013 | 1997 | 0.330 |
Why?
|
| Child | 9 | 2025 | 4483 | 0.320 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2014 | 65 | 0.320 |
Why?
|
| Cervix Uteri | 3 | 2007 | 58 | 0.310 |
Why?
|
| Serotyping | 11 | 2014 | 52 | 0.310 |
Why?
|
| Ebolavirus | 2 | 2022 | 39 | 0.310 |
Why?
|
| Health Services Research | 1 | 2010 | 270 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 476 | 0.300 |
Why?
|
| Infant, Newborn | 12 | 2022 | 1349 | 0.290 |
Why?
|
| Integrin alpha1beta1 | 1 | 2007 | 2 | 0.290 |
Why?
|
| Immunity, Maternally-Acquired | 5 | 2007 | 11 | 0.290 |
Why?
|
| Child, Preschool | 8 | 2025 | 1967 | 0.280 |
Why?
|
| Virulence Factors | 2 | 2008 | 85 | 0.280 |
Why?
|
| Zoonoses | 1 | 2006 | 9 | 0.270 |
Why?
|
| Information Dissemination | 2 | 2006 | 116 | 0.260 |
Why?
|
| Phylogeny | 5 | 2021 | 375 | 0.260 |
Why?
|
| Registries | 1 | 2010 | 878 | 0.260 |
Why?
|
| Sepsis | 3 | 2013 | 279 | 0.260 |
Why?
|
| Immunoglobulin G | 5 | 2007 | 467 | 0.260 |
Why?
|
| United States | 12 | 2024 | 7756 | 0.250 |
Why?
|
| Bacterial Capsules | 7 | 2008 | 18 | 0.240 |
Why?
|
| Public Health Surveillance | 2 | 2017 | 28 | 0.240 |
Why?
|
| Adolescent | 10 | 2025 | 6198 | 0.240 |
Why?
|
| Cattle Diseases | 1 | 2025 | 10 | 0.240 |
Why?
|
| Penicillin Resistance | 2 | 2015 | 11 | 0.240 |
Why?
|
| Milk | 1 | 2025 | 42 | 0.230 |
Why?
|
| Mice | 21 | 2013 | 10833 | 0.230 |
Why?
|
| Data Collection | 4 | 2019 | 384 | 0.230 |
Why?
|
| Tandem Repeat Sequences | 2 | 2001 | 26 | 0.230 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 63 | 0.230 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2005 | 125 | 0.230 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2025 | 71 | 0.230 |
Why?
|
| Drosophila melanogaster | 1 | 2008 | 490 | 0.230 |
Why?
|
| Biosurveillance | 2 | 2014 | 3 | 0.220 |
Why?
|
| Male | 17 | 2025 | 29597 | 0.210 |
Why?
|
| Rabbits | 11 | 2006 | 332 | 0.210 |
Why?
|
| Animals, Newborn | 9 | 2008 | 237 | 0.210 |
Why?
|
| Gene Expression Regulation, Bacterial | 3 | 2013 | 164 | 0.210 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 80 | 0.210 |
Why?
|
| Computer Systems | 2 | 2013 | 14 | 0.210 |
Why?
|
| Algorithms | 3 | 2024 | 1003 | 0.210 |
Why?
|
| Neglected Diseases | 2 | 2014 | 11 | 0.210 |
Why?
|
| Bedding and Linens | 1 | 2023 | 5 | 0.210 |
Why?
|
| Politics | 2 | 2020 | 34 | 0.200 |
Why?
|
| Carrier Proteins | 4 | 2005 | 706 | 0.200 |
Why?
|
| Actins | 1 | 2004 | 259 | 0.200 |
Why?
|
| Hepatitis E | 1 | 2022 | 1 | 0.200 |
Why?
|
| Hepatitis E virus | 1 | 2022 | 1 | 0.200 |
Why?
|
| Penile Diseases | 1 | 2022 | 7 | 0.200 |
Why?
|
| Quarantine | 1 | 2022 | 11 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2006 | 455 | 0.190 |
Why?
|
| Skin Ulcer | 1 | 2022 | 15 | 0.190 |
Why?
|
| Rectal Diseases | 1 | 2022 | 27 | 0.190 |
Why?
|
| Exanthema | 1 | 2022 | 27 | 0.190 |
Why?
|
| Viral Vaccines | 1 | 2002 | 49 | 0.190 |
Why?
|
| Protein Binding | 5 | 2009 | 1607 | 0.190 |
Why?
|
| Base Sequence | 9 | 2009 | 1335 | 0.190 |
Why?
|
| Cholera | 2 | 2011 | 14 | 0.190 |
Why?
|
| One Health | 1 | 2021 | 2 | 0.180 |
Why?
|
| Rec A Recombinases | 1 | 2001 | 35 | 0.180 |
Why?
|
| Crowding | 1 | 2021 | 34 | 0.180 |
Why?
|
| Refugees | 1 | 2022 | 70 | 0.180 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 43 | 0.180 |
Why?
|
| Adult | 13 | 2024 | 16675 | 0.170 |
Why?
|
| Mutation | 5 | 2020 | 2601 | 0.170 |
Why?
|
| Liver Abscess | 1 | 2000 | 18 | 0.170 |
Why?
|
| Salmonella enteritidis | 1 | 2020 | 5 | 0.170 |
Why?
|
| Mosaicism | 1 | 2000 | 30 | 0.170 |
Why?
|
| Forecasting | 2 | 2019 | 231 | 0.170 |
Why?
|
| Antigens, Viral | 1 | 2021 | 135 | 0.170 |
Why?
|
| Mumps virus | 1 | 2020 | 1 | 0.170 |
Why?
|
| Mumps | 1 | 2020 | 2 | 0.170 |
Why?
|
| Seasons | 2 | 2024 | 134 | 0.170 |
Why?
|
| Cell Line | 5 | 2008 | 2039 | 0.170 |
Why?
|
| Multigene Family | 1 | 2000 | 99 | 0.170 |
Why?
|
| Infant | 6 | 2025 | 1629 | 0.170 |
Why?
|
| Schools, Medical | 1 | 2021 | 145 | 0.170 |
Why?
|
| Vagina | 2 | 2004 | 85 | 0.170 |
Why?
|
| Genome, Bacterial | 3 | 2005 | 67 | 0.170 |
Why?
|
| RNA, Viral | 1 | 2021 | 276 | 0.160 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 34 | 0.160 |
Why?
|
| Phagocytosis | 7 | 2008 | 264 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 4 | 2014 | 787 | 0.160 |
Why?
|
| Duodenoscopes | 1 | 2019 | 2 | 0.160 |
Why?
|
| Pain | 1 | 2022 | 407 | 0.160 |
Why?
|
| Listeriosis | 1 | 2019 | 30 | 0.160 |
Why?
|
| Equipment Contamination | 1 | 2019 | 33 | 0.160 |
Why?
|
| Plants | 2 | 2012 | 49 | 0.160 |
Why?
|
| Risk Factors | 4 | 2023 | 5316 | 0.160 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 28 | 0.150 |
Why?
|
| Monkeypox virus | 3 | 2023 | 8 | 0.150 |
Why?
|
| Amino Acid Sequence | 7 | 2007 | 1595 | 0.150 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 57 | 0.150 |
Why?
|
| Binding Sites | 4 | 2009 | 903 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2020 | 215 | 0.140 |
Why?
|
| Streptococcus | 1 | 1997 | 17 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2019 | 307 | 0.140 |
Why?
|
| Young Adult | 5 | 2024 | 4651 | 0.140 |
Why?
|
| Machine Learning | 1 | 2019 | 175 | 0.140 |
Why?
|
| Epitopes | 3 | 1996 | 296 | 0.140 |
Why?
|
| Immunization, Passive | 4 | 1999 | 108 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2020 | 294 | 0.130 |
Why?
|
| Incidence | 4 | 2025 | 1374 | 0.130 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 4 | 0.130 |
Why?
|
| Cloning, Molecular | 5 | 2001 | 384 | 0.130 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 322 | 0.130 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 29 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 3 | 2007 | 670 | 0.120 |
Why?
|
| Mass Screening | 1 | 2021 | 687 | 0.120 |
Why?
|
| Bacterial Adhesion | 2 | 2007 | 63 | 0.120 |
Why?
|
| Uveitis | 1 | 2016 | 34 | 0.120 |
Why?
|
| Microscopy, Confocal | 2 | 2007 | 234 | 0.120 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2020 | 203 | 0.120 |
Why?
|
| Bacteremia | 4 | 2015 | 94 | 0.120 |
Why?
|
| Confidentiality | 1 | 2015 | 53 | 0.110 |
Why?
|
| Leishmaniasis | 1 | 2014 | 10 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 69 | 0.110 |
Why?
|
| Virulence | 6 | 2013 | 195 | 0.110 |
Why?
|
| Critical Care | 2 | 2020 | 392 | 0.110 |
Why?
|
| Travel | 2 | 2011 | 42 | 0.110 |
Why?
|
| Comorbidity | 2 | 2014 | 1119 | 0.110 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 774 | 0.110 |
Why?
|
| Logistic Models | 2 | 2014 | 1273 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2014 | 855 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2018 | 3264 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 4 | 2020 | 413 | 0.110 |
Why?
|
| Fimbriae, Bacterial | 1 | 2013 | 19 | 0.100 |
Why?
|
| Boston | 2 | 2020 | 251 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 259 | 0.100 |
Why?
|
| Sputum | 1 | 2012 | 37 | 0.100 |
Why?
|
| Social Class | 1 | 2013 | 133 | 0.100 |
Why?
|
| Coronavirus | 1 | 2012 | 14 | 0.100 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2012 | 24 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 3 | 2001 | 516 | 0.100 |
Why?
|
| Government | 1 | 2012 | 8 | 0.100 |
Why?
|
| Disease Notification | 1 | 2012 | 5 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 1141 | 0.100 |
Why?
|
| Private Sector | 1 | 2012 | 12 | 0.100 |
Why?
|
| Contact Tracing | 2 | 2022 | 17 | 0.100 |
Why?
|
| Cell Wall | 1 | 2013 | 118 | 0.100 |
Why?
|
| Middle Aged | 6 | 2024 | 17409 | 0.090 |
Why?
|
| Fungi | 1 | 2012 | 57 | 0.090 |
Why?
|
| Mycoses | 1 | 2012 | 46 | 0.090 |
Why?
|
| Ecosystem | 1 | 2012 | 55 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2004 | 670 | 0.090 |
Why?
|
| Vibrio cholerae | 1 | 2011 | 18 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2007 | 1460 | 0.090 |
Why?
|
| Molecular Epidemiology | 2 | 2021 | 32 | 0.090 |
Why?
|
| Communication | 1 | 2016 | 569 | 0.090 |
Why?
|
| Diarrhea | 1 | 2011 | 76 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 2181 | 0.090 |
Why?
|
| Length of Stay | 1 | 2014 | 806 | 0.090 |
Why?
|
| Amino Acid Motifs | 2 | 2009 | 153 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2012 | 271 | 0.090 |
Why?
|
| Immune Sera | 4 | 1999 | 35 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 976 | 0.090 |
Why?
|
| Schools | 2 | 2022 | 159 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 1992 | 869 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1558 | 0.080 |
Why?
|
| Immunoglobulin M | 2 | 2007 | 116 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2008 | 701 | 0.080 |
Why?
|
| Immunoglobulin A | 3 | 2007 | 97 | 0.080 |
Why?
|
| Asthma | 1 | 2014 | 432 | 0.080 |
Why?
|
| Central America | 1 | 2009 | 2 | 0.080 |
Why?
|
| Mexico | 1 | 2009 | 39 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2007 | 247 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2000 | 364 | 0.080 |
Why?
|
| Blotting, Western | 4 | 2001 | 611 | 0.080 |
Why?
|
| Species Specificity | 2 | 2006 | 336 | 0.070 |
Why?
|
| Molecular Weight | 2 | 2000 | 188 | 0.070 |
Why?
|
| Crystallography, X-Ray | 2 | 2007 | 432 | 0.070 |
Why?
|
| Lactic Acid | 1 | 2008 | 75 | 0.070 |
Why?
|
| Streptococcus pyogenes | 2 | 2005 | 31 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2008 | 166 | 0.070 |
Why?
|
| Animals, Outbred Strains | 2 | 2007 | 7 | 0.070 |
Why?
|
| Spleen | 2 | 2001 | 482 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 193 | 0.070 |
Why?
|
| Bacterial Typing Techniques | 1 | 2007 | 13 | 0.070 |
Why?
|
| Genital Diseases, Female | 1 | 2007 | 15 | 0.070 |
Why?
|
| DNA, Bacterial | 4 | 2006 | 267 | 0.070 |
Why?
|
| Subcellular Fractions | 2 | 2004 | 68 | 0.070 |
Why?
|
| Time Factors | 3 | 2016 | 3752 | 0.070 |
Why?
|
| Cross Reactions | 2 | 1997 | 131 | 0.070 |
Why?
|
| Aged | 5 | 2024 | 14283 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2006 | 75 | 0.060 |
Why?
|
| Point Mutation | 1 | 2007 | 166 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 70 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 240 | 0.060 |
Why?
|
| DNA Primers | 2 | 1996 | 293 | 0.060 |
Why?
|
| Genomics | 1 | 2009 | 369 | 0.060 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2025 | 5 | 0.060 |
Why?
|
| Conserved Sequence | 2 | 2009 | 174 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 191 | 0.060 |
Why?
|
| Dairying | 1 | 2025 | 2 | 0.060 |
Why?
|
| Cross Infection | 1 | 2007 | 160 | 0.060 |
Why?
|
| Serogroup | 1 | 2025 | 35 | 0.060 |
Why?
|
| RNA Interference | 1 | 2008 | 619 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2005 | 55 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6566 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 1541 | 0.060 |
Why?
|
| Chlorates | 1 | 2004 | 2 | 0.060 |
Why?
|
| Digitonin | 1 | 2004 | 4 | 0.060 |
Why?
|
| Cattle | 1 | 2025 | 309 | 0.060 |
Why?
|
| Cytochalasin D | 1 | 2004 | 18 | 0.060 |
Why?
|
| Polysaccharide-Lyases | 1 | 2004 | 3 | 0.060 |
Why?
|
| Cytotoxins | 1 | 2004 | 12 | 0.060 |
Why?
|
| Sequence Alignment | 2 | 2005 | 300 | 0.050 |
Why?
|
| World Health Organization | 2 | 2016 | 34 | 0.050 |
Why?
|
| Codon, Initiator | 1 | 2003 | 11 | 0.050 |
Why?
|
| Immunoassay | 1 | 2004 | 70 | 0.050 |
Why?
|
| Hospitals | 1 | 2007 | 393 | 0.050 |
Why?
|
| Transcription Initiation Site | 1 | 2003 | 49 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2004 | 61 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2007 | 1146 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2003 | 150 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 128 | 0.050 |
Why?
|
| Lung | 1 | 2008 | 942 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2024 | 119 | 0.050 |
Why?
|
| Cytosol | 1 | 2004 | 180 | 0.050 |
Why?
|
| Heparin | 1 | 2004 | 116 | 0.050 |
Why?
|
| Trifluridine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Isoindoles | 1 | 2022 | 3 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2003 | 256 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 411 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3027 | 0.050 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2002 | 5 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2004 | 277 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 179 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2002 | 17 | 0.050 |
Why?
|
| Protein Transport | 1 | 2004 | 402 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 52 | 0.050 |
Why?
|
| Anus Diseases | 1 | 2022 | 8 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 14 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2022 | 20 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 545 | 0.050 |
Why?
|
| Cell Polarity | 1 | 2002 | 110 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 121 | 0.050 |
Why?
|
| Kinetics | 1 | 2004 | 764 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 364 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 864 | 0.050 |
Why?
|
| Microfluidics | 1 | 2022 | 25 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 113 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2022 | 97 | 0.050 |
Why?
|
| Biological Transport | 1 | 2002 | 293 | 0.050 |
Why?
|
| Genetic Variation | 3 | 2007 | 385 | 0.050 |
Why?
|
| Masks | 1 | 2021 | 23 | 0.050 |
Why?
|
| Dominican Republic | 2 | 2011 | 25 | 0.050 |
Why?
|
| Rectum | 1 | 2022 | 88 | 0.050 |
Why?
|
| Models, Animal | 1 | 2002 | 236 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2004 | 493 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 32 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2005 | 76 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 198 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 62 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 104 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2009 | 1512 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 29 | 0.040 |
Why?
|
| Suppuration | 1 | 2000 | 12 | 0.040 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2000 | 8 | 0.040 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 84 | 0.040 |
Why?
|
| Authoritarianism | 1 | 2020 | 1 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 1184 | 0.040 |
Why?
|
| Cytokines | 1 | 2004 | 934 | 0.040 |
Why?
|
| Candida | 1 | 2020 | 38 | 0.040 |
Why?
|
| Prejudice | 1 | 2020 | 61 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 1999 | 14 | 0.040 |
Why?
|
| Community Health Services | 1 | 2021 | 127 | 0.040 |
Why?
|
| Temperature | 1 | 2021 | 309 | 0.040 |
Why?
|
| Drainage | 1 | 2000 | 154 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 127 | 0.040 |
Why?
|
| Colistin | 1 | 2019 | 7 | 0.040 |
Why?
|
| Enterococcus faecium | 1 | 1999 | 7 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2019 | 34 | 0.040 |
Why?
|
| Enterococcus faecalis | 1 | 1999 | 12 | 0.040 |
Why?
|
| Gene Expression | 2 | 2005 | 838 | 0.040 |
Why?
|
| Students | 1 | 2021 | 216 | 0.040 |
Why?
|
| Food Handling | 1 | 2019 | 51 | 0.040 |
Why?
|
| Vancomycin | 1 | 1999 | 39 | 0.040 |
Why?
|
| Lethal Dose 50 | 1 | 1998 | 15 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 250 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2000 | 479 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 1997 | 12 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2020 | 261 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 180 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 665 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2017 | 23 | 0.040 |
Why?
|
| Software Design | 1 | 2017 | 28 | 0.040 |
Why?
|
| Information Systems | 1 | 2017 | 29 | 0.030 |
Why?
|
| Climate Change | 1 | 2017 | 24 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 5417 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 432 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2007 | 73 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2007 | 103 | 0.030 |
Why?
|
| Immunochemistry | 1 | 1997 | 10 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 104 | 0.030 |
Why?
|
| Curriculum | 1 | 2021 | 589 | 0.030 |
Why?
|
| Trypsin | 1 | 1996 | 39 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 1996 | 19 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1997 | 72 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 990 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2017 | 170 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 154 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2017 | 230 | 0.030 |
Why?
|
| Liberia | 1 | 2016 | 11 | 0.030 |
Why?
|
| Pakistan | 1 | 2016 | 15 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 363 | 0.030 |
Why?
|
| Endopeptidases | 2 | 1999 | 67 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 369 | 0.030 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2015 | 1 | 0.030 |
Why?
|
| Epidemiology | 1 | 2015 | 6 | 0.030 |
Why?
|
| Penicillins | 1 | 2014 | 30 | 0.030 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2014 | 16 | 0.030 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2014 | 14 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 313 | 0.030 |
Why?
|
| France | 1 | 2014 | 14 | 0.030 |
Why?
|
| Escherichia coli | 2 | 1997 | 708 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 53 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2007 | 1116 | 0.030 |
Why?
|
| Social Media | 1 | 2016 | 128 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 223 | 0.030 |
Why?
|
| Heat-Shock Response | 1 | 2013 | 34 | 0.030 |
Why?
|
| Middle East | 1 | 2012 | 10 | 0.030 |
Why?
|
| Opsonin Proteins | 2 | 2005 | 31 | 0.030 |
Why?
|
| Extinction, Biological | 1 | 2012 | 8 | 0.020 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 89 | 0.020 |
Why?
|
| Vibrio cholerae O1 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 265 | 0.020 |
Why?
|
| Haiti | 1 | 2011 | 15 | 0.020 |
Why?
|
| Food Supply | 1 | 2012 | 53 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 1991 | 26 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 274 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2011 | 49 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1991 | 204 | 0.020 |
Why?
|
| Feces | 1 | 2011 | 112 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1997 | 894 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 89 | 0.020 |
Why?
|
| Poverty | 1 | 2012 | 295 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1081 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 671 | 0.020 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1989 | 8 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1991 | 894 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 51 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 69 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 968 | 0.020 |
Why?
|
| Fetus | 1 | 2008 | 99 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2007 | 25 | 0.020 |
Why?
|
| Phenotype | 1 | 1991 | 1198 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2008 | 455 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 1348 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 1989 | 568 | 0.020 |
Why?
|
| Immunodiffusion | 1 | 2006 | 5 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 1991 | 348 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 674 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2007 | 308 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2005 | 41 | 0.010 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2005 | 10 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2652 | 0.010 |
Why?
|
| Crystallization | 1 | 2005 | 99 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 1981 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 88 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 160 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 5603 | 0.010 |
Why?
|
| Computational Biology | 1 | 2005 | 354 | 0.010 |
Why?
|
| Neutrophils | 1 | 2005 | 376 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2002 | 120 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 613 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 298 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 2158 | 0.010 |
Why?
|
| Peritoneum | 1 | 1999 | 29 | 0.010 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 1999 | 3 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1999 | 46 | 0.010 |
Why?
|
| Uterus | 1 | 1999 | 42 | 0.010 |
Why?
|
| Biomass | 1 | 1999 | 29 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1999 | 32 | 0.010 |
Why?
|
| Random Allocation | 1 | 1999 | 198 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1999 | 97 | 0.010 |
Why?
|
| Hemolysin Proteins | 1 | 1999 | 44 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1999 | 48 | 0.010 |
Why?
|
| Gestational Age | 1 | 1999 | 189 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1997 | 50 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 1997 | 56 | 0.010 |
Why?
|
| Spain | 1 | 1993 | 33 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1993 | 60 | 0.010 |
Why?
|
| TATA Box | 1 | 1992 | 11 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 52 | 0.010 |
Why?
|
| Protein Sorting Signals | 1 | 1992 | 55 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 182 | 0.010 |
Why?
|
| Plasmids | 1 | 1991 | 292 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 1991 | 136 | 0.010 |
Why?
|
| Mycobacterium avium Complex | 1 | 1989 | 3 | 0.000 |
Why?
|
| Prevalence | 1 | 1993 | 1365 | 0.000 |
Why?
|
| Toxoplasma | 1 | 1989 | 33 | 0.000 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 138 | 0.000 |
Why?
|
| Monocytes | 1 | 1989 | 353 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1989 | 251 | 0.000 |
Why?
|
| Macrophages | 1 | 1989 | 1039 | 0.000 |
Why?
|